GENIL Stock Overview
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₺58.00 |
| 52 Week High | ₺84.50 |
| 52 Week Low | ₺35.94 |
| Beta | 1.23 |
| 1 Month Change | -24.58% |
| 3 Month Change | 19.24% |
| 1 Year Change | 20.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 390.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENIL | TR Pharmaceuticals | TR Market | |
|---|---|---|---|
| 7D | -6.5% | -2.1% | -2.8% |
| 1Y | 20.8% | -0.8% | 113.8% |
Return vs Industry: GENIL exceeded the TR Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: GENIL underperformed the TR Market which returned 112.1% over the past year.
Price Volatility
| GENIL volatility | |
|---|---|
| GENIL Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in TR Market | 11.8% |
| 10% least volatile stocks in TR Market | 5.5% |
Stable Share Price: GENIL's share price has been volatile over the past 3 months.
Volatility Over Time: GENIL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 622 | Abidin Gulmus | www.genilac.com.tr |
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration and licensing agreement with Sulfateq BV for the development and commercialization of the original molecule SUL-238 as a unique treatment for Alzheimer's disease and other neurodegenerative diseases.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Fundamentals Summary
| GENIL fundamental statistics | |
|---|---|
| Market cap | ₺17.40b |
| Earnings (TTM) | ₺454.58m |
| Revenue (TTM) | ₺8.15b |
38.3x
P/E Ratio2.1x
P/S RatioIs GENIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENIL income statement (TTM) | |
|---|---|
| Revenue | ₺8.15b |
| Cost of Revenue | ₺6.36b |
| Gross Profit | ₺1.79b |
| Other Expenses | ₺1.34b |
| Earnings | ₺454.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.52 |
| Gross Margin | 21.99% |
| Net Profit Margin | 5.58% |
| Debt/Equity Ratio | 25.6% |
How did GENIL perform over the long term?
See historical performance and comparison